1. Induced pluripotent stem cell (iPSC) line MLi005-A derived from a patient with dominant dystrophic epidermolysis bullosa (DDEB).
- Author
-
Ropret, Sandra, Khurana, Preeti, Fabčič, Tara, Cvetkovska, Janina, Trobec, Ana, Jokhadar, Špela Zemljič, Ilic, Dusko, McGrath, John A, Guttmann-Gruber, Christina, and Liovic, Mirjana
- Abstract
• First fully characterised iPSC line derived from a dominant dystrophic EB patient (DDEB) • Mli005-A carries the most common recurrent autosomal dominant COL7A1 mutation in cases of DDEB. • Mli005-A is a powerful tool for studies on DDEB disease mechanisms, skin barrier function and drug screening and therapy development. We have generated MLi005-A, a new induced pluripotent stem cell (iPSC) line derived from skin fibroblasts of a male patient with dominant dystrophic epidermolysis bullosa (DDEB). This iPSC line may be used as a model system for studies on skin integrity, the extracellular matrix and skin barrier function. The characterization of the MLi005-A cell line consisted of molecular karyotyping, next-generation sequencing of the COL7A1 alleles, pluripotency and differentiation potentials testing by immunofluorescence of associated markers in vitro. The MLi-005A line has been also tested for ability to differentiate into fibroblasts and keratinocytes and markers associated with these cell types. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF